Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548691 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 513
- Enrollment target
NCT00548691 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 513 participants.
The verdict
NCT00548691, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 513 participants
- Enrollment target
Study Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
Interventions
- DRUG Ferric Carboxymaltose
- DRUG Standard Medical Care (SMC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548691
The ClinicalTrials.gov registry entry for NCT00548691 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 513 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose is the first listed.
NCT00548691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548691 about?
NCT00548691 is a clinical study titled "Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients". The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
What is the current status of trial NCT00548691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 513 participants. The study started on 2007-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00548691?
The interventions under investigation include: Ferric Carboxymaltose (DRUG), Standard Medical Care (SMC) (DRUG).
Who is sponsoring clinical trial NCT00548691?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.